Clinical Trials Logo
  1. Home
  2. Peanut Hypersensitivity
  3. NCT00382148

A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

Peanut Hypersensitivity Clinical Trial

Official title:
A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)

Clinical Trial Summary

This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00382148
Study type Interventional
Source Genentech, Inc.
Contact
Status Completed
Phase Phase 2
Start date November 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Recruiting NCT00243555 - Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut N/A
Recruiting NCT01429896 - The Effect of Extrinsic Factors on Food Allergy Phase 2
Completed NCT00850668 - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults Phase 1
Active, not recruiting NCT04090203 - Boiled Peanut Oral Immunotherapy Phase 1
Completed NCT01084174 - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Phase 1/Phase 2
Recruiting NCT05695261 - Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients Phase 2
Completed NCT01373242 - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Phase 1/Phase 2
Completed NCT02424136 - PEAnut Anaphylaxis Predictors N/A
Completed NCT00932282 - Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy Phase 1/Phase 2
Completed NCT00356174 - An Observational Study of Childhood Food Allergy N/A
Completed NCT02304991 - FARE Peanut SLIT and Early Tolerance Induction Phase 2
Recruiting NCT05621317 - A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy Phase 2
Recruiting NCT03679676 - Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) Phase 2
Completed NCT00580606 - A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial Phase 1/Phase 2
Completed NCT02665793 - Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study N/A
Completed NCT01867671 - Peanut Oral Immunotherapy in Children Phase 2
Active, not recruiting NCT03937726 - Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy N/A
Completed NCT00815035 - Oral Immunotherapy (OIT) for Peanut Allergy Phase 2
Completed NCT01891136 - Oral Peanut Immunotherapy for Peanut Allergic Patients Phase 0